Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

895
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
895
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

904
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
904
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

686
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
686
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

940
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
940
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

2.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.7K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

5.8K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual arrestin-1: how did we learn what we know today about this protein?

Progress in retinal and eye research·2026
Same author

Arrestin-3 promotes locomotor sensitization to psychostimulants via JNK signaling in nucleus accumbens.

bioRxiv : the preprint server for biology·2026
Same author

GRKs and arrestins: Nomenclature and functions in GPCR-dependent and -independent signalling.

British journal of pharmacology·2026
Same author

Arrestin-3 sca-olds multiple MAP3Ks driving stress-induced JNK3 activation and cell death.

bioRxiv : the preprint server for biology·2026
Same author

Cytoplasmic tail diversity determines the effector bias of the adhesion GPCR ADGRL2.

Cell chemical biology·2026
Same author

Deceptive beauty of non-natural structures.

Protein science : a publication of the Protein Society·2026

Related Experiment Video

Updated: Aug 3, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.9K

β-Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives.

Jürgen Wess1, Antwi-Boasiako Oteng2, Osvaldo Rivera-Gonzalez2

  • 1Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (J.W., A.-B.O., O.R.-G.); and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee (E.V.G., V.V.G.) jurgenw@niddk.nih.gov Vsevolod.Gurevich@vanderbilt.edu.

Pharmacological Reviews
|April 7, 2023
PubMed
Summary

Beta-arrestins (arrestin-2 and -3) are key intracellular proteins regulating numerous cellular pathways. Research reveals their roles in the central nervous system, cancer, and metabolism, suggesting new therapeutic targets.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

12.5K
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.5K

Related Experiment Videos

Last Updated: Aug 3, 2025

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

6.9K
Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

12.5K
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.5K

Area of Science:

  • Molecular and Cellular Biology
  • Physiology
  • Pharmacology

Background:

  • Beta-arrestins (arrestin-2 and -3) are multifunctional proteins initially identified for their role in G protein-coupled receptor (GPCR) signaling.
  • Beyond GPCRs, they modulate diverse cellular processes through GPCR-dependent and -independent mechanisms.
  • Recent structural and biochemical studies offer new insights into beta-arrestin interactions with receptors and effectors.

Purpose of the Study:

  • To review the physiological functions regulated by beta-arrestin-1 and beta-arrestin-2.
  • To focus on the roles of beta-arrestins in the central nervous system, carcinogenesis, and metabolic homeostasis.
  • To explore potential therapeutic strategies targeting beta-arrestin signaling pathways.

Main Methods:

  • Review of recent structural, biophysical, and biochemical studies on beta-arrestins.
  • Analysis of data from beta-arrestin mutant mouse models and cultured cells.
  • Synthesis of findings related to beta-arrestin functions in various physiological and pathophysiological contexts.

Main Results:

  • Beta-arrestins regulate a wide array of cellular signaling pathways and physiological functions.
  • Studies highlight their critical roles in the central nervous system, cancer development, and metabolic regulation (glucose and energy homeostasis).
  • Novel structural insights explain beta-arrestin binding to GPCRs and downstream proteins.

Conclusions:

  • Beta-arrestins are evolutionarily conserved, multifunctional proteins with broad physiological impact.
  • Understanding their structure-function relationships is crucial for deciphering their roles in health and disease.
  • Targeting specific beta-arrestin pathways holds promise for developing novel therapeutics.